Blue rubber bleb nevus syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
== Medical Therapy == | == Medical Therapy == | ||
* Pharmacologic medical therapies for [[blue rubber bleb nevus syndrome]] include:<ref name="pmid19958301">{{cite journal |vauthors=Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A |title=Blue rubber bleb nevus syndrome |journal=Acta Paediatr. |volume=99 |issue=4 |pages=632–5 |date=April 2010 |pmid=19958301 |doi=10.1111/j.1651-2227.2009.01608.x |url=}}</ref><ref name="pmid9795507">{{cite journal |vauthors=Jain A, Kar P, Chander R, Khandpur S, Jain S, Prabhash K, Gangwal P |title=Blue rubber bleb nevus syndrome: a cause of gastrointestinal hemorrhage |journal=Indian J Gastroenterol |volume=17 |issue=4 |pages=153–4 |date=1998 |pmid=9795507 |doi= |url=}}</ref><ref name="Jin2014">{{cite journal|last1=Jin|first1=Xue-Li|title=Blue rubber bleb nevus syndrome: A case report and literature review|journal=World Journal of Gastroenterology|volume=20|issue=45|year=2014|pages=17254|issn=1007-9327|doi=10.3748/wjg.v20.i45.17254}}</ref><ref name="BoenteCordisco1999">{{cite journal|last1=Boente|first1=Maria del C.|last2=Cordisco|first2=Maria R.|last3=Frontini|first3=Maria del V.|last4=Asial|first4=Raul A.|title=Blue Rubber Bleb Nevus (Bean Syndrome): Evolution of Four Cases and Clinical Response to Pharmacologic Agents|journal=Pediatric Dermatology|volume=16|issue=3|year=1999|pages=222–227|issn=0736-8046|doi=10.1046/j.1525-1470.1999.00065.x}}</ref><ref name="OguAbusin2018">{{cite journal|last1=Ogu|first1=Ugochi O.|last2=Abusin|first2=Ghada|last3=Abu-Arja|first3=Rolla F.|last4=Staber|first4=Janice M.|title=Successful Management of Blue Rubber Bleb Nevus Syndrome (BRBNS) with Sirolimus|journal=Case Reports in Pediatrics|volume=2018|year=2018|pages=1–5|issn=2090-6803|doi=10.1155/2018/7654278}}</ref> | * Pharmacologic medical therapies for [[blue rubber bleb nevus syndrome]] include:<ref name="pmid19958301">{{cite journal |vauthors=Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A |title=Blue rubber bleb nevus syndrome |journal=Acta Paediatr. |volume=99 |issue=4 |pages=632–5 |date=April 2010 |pmid=19958301 |doi=10.1111/j.1651-2227.2009.01608.x |url=}}</ref><ref name="pmid9795507">{{cite journal |vauthors=Jain A, Kar P, Chander R, Khandpur S, Jain S, Prabhash K, Gangwal P |title=Blue rubber bleb nevus syndrome: a cause of gastrointestinal hemorrhage |journal=Indian J Gastroenterol |volume=17 |issue=4 |pages=153–4 |date=1998 |pmid=9795507 |doi= |url=}}</ref><ref name="Jin2014">{{cite journal|last1=Jin|first1=Xue-Li|title=Blue rubber bleb nevus syndrome: A case report and literature review|journal=World Journal of Gastroenterology|volume=20|issue=45|year=2014|pages=17254|issn=1007-9327|doi=10.3748/wjg.v20.i45.17254}}</ref><ref name="BoenteCordisco1999">{{cite journal|last1=Boente|first1=Maria del C.|last2=Cordisco|first2=Maria R.|last3=Frontini|first3=Maria del V.|last4=Asial|first4=Raul A.|title=Blue Rubber Bleb Nevus (Bean Syndrome): Evolution of Four Cases and Clinical Response to Pharmacologic Agents|journal=Pediatric Dermatology|volume=16|issue=3|year=1999|pages=222–227|issn=0736-8046|doi=10.1046/j.1525-1470.1999.00065.x}}</ref><ref name="OguAbusin2018">{{cite journal|last1=Ogu|first1=Ugochi O.|last2=Abusin|first2=Ghada|last3=Abu-Arja|first3=Rolla F.|last4=Staber|first4=Janice M.|title=Successful Management of Blue Rubber Bleb Nevus Syndrome (BRBNS) with Sirolimus|journal=Case Reports in Pediatrics|volume=2018|year=2018|pages=1–5|issn=2090-6803|doi=10.1155/2018/7654278}}</ref> | ||
** Preferred regimen (1):[[Interferon-beta]], 1.2 mg/m<sup>2</sup>/day for 2 month | ** Preferred regimen (1): [[Interferon-beta]], 1.2 mg/m<sup>2</sup>/day for 2 month | ||
** Preferred regimen (2):[[Octreotide]], 5.7 microg/kg subcutaneously twice daily for 4 weeks<ref name="pmid11568521">{{cite journal |vauthors=Gonzalez D, Elizondo BJ, Haslag S, Buchanan G, Burdick JS, Guzzetta PC, Hicks BA, Andersen JM |title=Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome |journal=J. Pediatr. Gastroenterol. Nutr. |volume=33 |issue=2 |pages=183–8 |date=August 2001 |pmid=11568521 |doi= |url=}}</ref> | ** Preferred regimen (2): [[Octreotide]], 5.7 microg/kg [[Subcutaneous|subcutaneously]] twice daily for 4 weeks<ref name="pmid11568521">{{cite journal |vauthors=Gonzalez D, Elizondo BJ, Haslag S, Buchanan G, Burdick JS, Guzzetta PC, Hicks BA, Andersen JM |title=Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome |journal=J. Pediatr. Gastroenterol. Nutr. |volume=33 |issue=2 |pages=183–8 |date=August 2001 |pmid=11568521 |doi= |url=}}</ref> | ||
** Preferred regimen (3):[[Sirolimus]],1.2 mg/m<sup>2</sup>/day for 2 months <ref name="pmid27820137">{{cite journal |vauthors=Ünlüsoy Aksu A, Sari S, Eğritaş Gürkan Ö, Dalgiç B |title=Favorable Response to Sirolimus in a Child With Blue Rubber Bleb Nevus Syndrome in the Gastrointestinal Tract |journal=J. Pediatr. Hematol. Oncol. |volume=39 |issue=2 |pages=147–149 |date=March 2017 |pmid=27820137 |doi=10.1097/MPH.0000000000000681 |url=}}</ref> | ** Preferred regimen (3): [[Sirolimus]],1.2 mg/m<sup>2</sup>/day for 2 months <ref name="pmid27820137">{{cite journal |vauthors=Ünlüsoy Aksu A, Sari S, Eğritaş Gürkan Ö, Dalgiç B |title=Favorable Response to Sirolimus in a Child With Blue Rubber Bleb Nevus Syndrome in the Gastrointestinal Tract |journal=J. Pediatr. Hematol. Oncol. |volume=39 |issue=2 |pages=147–149 |date=March 2017 |pmid=27820137 |doi=10.1097/MPH.0000000000000681 |url=}}</ref> | ||
** Preferred regimen (4):[[Iron]] supplementation | ** Preferred regimen (4): [[Iron]] supplementation | ||
** Preferred regimen (5):[[Blood transfusions]] | ** Preferred regimen (5): [[Blood transfusions]] | ||
** Preferred regimen (6):[[Corticosteroids]] | ** Preferred regimen (6): [[Corticosteroids]] | ||
** Preferred regimen (7):[[Propranolol]], 40 mg twice daily; titrate weekly as needed based on patient response | ** Preferred regimen (7): [[Propranolol]], 40 mg twice daily; [[titrate]] weekly as needed based on [[patient]] response | ||
** Preferred regimen (8):[[Thalidomide]] | ** Preferred regimen (8): [[Thalidomide]] | ||
{{Blue rubber bleb nevus syndrome}} | {{Blue rubber bleb nevus syndrome}} | ||
==References== | ==References== | ||
Latest revision as of 23:18, 27 January 2020
|
Blue rubber bleb nevus syndrome Microchapters |
|
Differentiating Blue Rubber Bleb Nevus Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Blue rubber bleb nevus syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Blue rubber bleb nevus syndrome medical therapy |
|
Directions to Hospitals Treating Blue rubber bleb nevus syndrome |
|
Risk calculators and risk factors for Blue rubber bleb nevus syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Vamsikrishna Gunnam M.B.B.S [2]
Overview
The mainstay of treatment for blue rubber bleb nevus syndrome is interferon-beta, octreotide, iron supplementation and blood transfusions.
Medical Therapy
- Pharmacologic medical therapies for blue rubber bleb nevus syndrome include:[1][2][3][4][5]
- Preferred regimen (1): Interferon-beta, 1.2 mg/m2/day for 2 month
- Preferred regimen (2): Octreotide, 5.7 microg/kg subcutaneously twice daily for 4 weeks[6]
- Preferred regimen (3): Sirolimus,1.2 mg/m2/day for 2 months [7]
- Preferred regimen (4): Iron supplementation
- Preferred regimen (5): Blood transfusions
- Preferred regimen (6): Corticosteroids
- Preferred regimen (7): Propranolol, 40 mg twice daily; titrate weekly as needed based on patient response
- Preferred regimen (8): Thalidomide
|
Blue rubber bleb nevus syndrome Microchapters |
|
Differentiating Blue Rubber Bleb Nevus Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Blue rubber bleb nevus syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Blue rubber bleb nevus syndrome medical therapy |
|
Directions to Hospitals Treating Blue rubber bleb nevus syndrome |
|
Risk calculators and risk factors for Blue rubber bleb nevus syndrome medical therapy |
References
- ↑ Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A (April 2010). "Blue rubber bleb nevus syndrome". Acta Paediatr. 99 (4): 632–5. doi:10.1111/j.1651-2227.2009.01608.x. PMID 19958301.
- ↑ Jain A, Kar P, Chander R, Khandpur S, Jain S, Prabhash K, Gangwal P (1998). "Blue rubber bleb nevus syndrome: a cause of gastrointestinal hemorrhage". Indian J Gastroenterol. 17 (4): 153–4. PMID 9795507.
- ↑ Jin, Xue-Li (2014). "Blue rubber bleb nevus syndrome: A case report and literature review". World Journal of Gastroenterology. 20 (45): 17254. doi:10.3748/wjg.v20.i45.17254. ISSN 1007-9327.
- ↑ Boente, Maria del C.; Cordisco, Maria R.; Frontini, Maria del V.; Asial, Raul A. (1999). "Blue Rubber Bleb Nevus (Bean Syndrome): Evolution of Four Cases and Clinical Response to Pharmacologic Agents". Pediatric Dermatology. 16 (3): 222–227. doi:10.1046/j.1525-1470.1999.00065.x. ISSN 0736-8046.
- ↑ Ogu, Ugochi O.; Abusin, Ghada; Abu-Arja, Rolla F.; Staber, Janice M. (2018). "Successful Management of Blue Rubber Bleb Nevus Syndrome (BRBNS) with Sirolimus". Case Reports in Pediatrics. 2018: 1–5. doi:10.1155/2018/7654278. ISSN 2090-6803.
- ↑ Gonzalez D, Elizondo BJ, Haslag S, Buchanan G, Burdick JS, Guzzetta PC, Hicks BA, Andersen JM (August 2001). "Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome". J. Pediatr. Gastroenterol. Nutr. 33 (2): 183–8. PMID 11568521.
- ↑ Ünlüsoy Aksu A, Sari S, Eğritaş Gürkan Ö, Dalgiç B (March 2017). "Favorable Response to Sirolimus in a Child With Blue Rubber Bleb Nevus Syndrome in the Gastrointestinal Tract". J. Pediatr. Hematol. Oncol. 39 (2): 147–149. doi:10.1097/MPH.0000000000000681. PMID 27820137.